550 related articles for article (PubMed ID: 25382430)
1. Selective inhibitors of zinc-dependent histone deacetylases. Therapeutic targets relevant to cancer.
Kollar J; Frecer V
Curr Pharm Des; 2015; 21(11):1472-502. PubMed ID: 25382430
[TBL] [Abstract][Full Text] [Related]
2. Histone Deacetylase Inhibitors Modulating Non-epigenetic Players: The Novel Mechanism for Small Molecule Based Therapeutic Intervention.
Ganai SA
Curr Drug Targets; 2018; 19(6):593-601. PubMed ID: 27231104
[TBL] [Abstract][Full Text] [Related]
3. Protein deacetylases: enzymes with functional diversity as novel therapeutic targets.
Yoshida M; Shimazu T; Matsuyama A
Prog Cell Cycle Res; 2003; 5():269-78. PubMed ID: 14593721
[TBL] [Abstract][Full Text] [Related]
4. Natural products as zinc-dependent histone deacetylase inhibitors.
Tan S; Liu ZP
ChemMedChem; 2015 Mar; 10(3):441-50. PubMed ID: 25581683
[TBL] [Abstract][Full Text] [Related]
5. The clinical development of histone deacetylase inhibitors as targeted anticancer drugs.
Marks PA
Expert Opin Investig Drugs; 2010 Sep; 19(9):1049-66. PubMed ID: 20687783
[TBL] [Abstract][Full Text] [Related]
6. Development and therapeutic impact of HDAC6-selective inhibitors.
Dallavalle S; Pisano C; Zunino F
Biochem Pharmacol; 2012 Sep; 84(6):756-65. PubMed ID: 22728920
[TBL] [Abstract][Full Text] [Related]
7. HDACs and HDAC Inhibitors in Cancer Development and Therapy.
Li Y; Seto E
Cold Spring Harb Perspect Med; 2016 Oct; 6(10):. PubMed ID: 27599530
[TBL] [Abstract][Full Text] [Related]
8. Focus on acetylation: the role of histone deacetylase inhibitors in cancer therapy and beyond.
Konstantinopoulos PA; Karamouzis MV; Papavassiliou AG
Expert Opin Investig Drugs; 2007 May; 16(5):569-71. PubMed ID: 17461732
[TBL] [Abstract][Full Text] [Related]
9. Toward isozyme-selective inhibitors of histone deacetylase as therapeutic agents for the treatment of cancer.
Ononye SN; van Heyst M; Falcone EM; Anderson AC; Wright DL
Pharm Pat Anal; 2012 May; 1(2):207-21. PubMed ID: 24163736
[TBL] [Abstract][Full Text] [Related]
10. Targeting the epigenome: Screening bioactive compounds that regulate histone deacetylase activity.
Godoy LD; Lucas JE; Bender AJ; Romanick SS; Ferguson BS
Mol Nutr Food Res; 2017 Apr; 61(4):. PubMed ID: 27981795
[TBL] [Abstract][Full Text] [Related]
11. Histone deacetylase inhibitors: design, structure-activity relationships and therapeutic implications for cancer.
Marson CM
Anticancer Agents Med Chem; 2009 Jul; 9(6):661-92. PubMed ID: 19601748
[TBL] [Abstract][Full Text] [Related]
12. Zinc Dependent Histone Deacetylase Inhibitors in Cancer Therapeutics: Recent Update.
Sultana F; Manasa KL; Shaik SP; Bonam SR; Kamal A
Curr Med Chem; 2019; 26(40):7212-7280. PubMed ID: 29852860
[TBL] [Abstract][Full Text] [Related]
13. From discovery to the coming generation of histone deacetylase inhibitors.
Yoshida M; Matsuyama A; Komatsu Y; Nishino N
Curr Med Chem; 2003 Nov; 10(22):2351-8. PubMed ID: 14529478
[TBL] [Abstract][Full Text] [Related]
14. Histone Deacetylase Inhibitors as Multitarget-Directed Epi-Drugs in Blocking PI3K Oncogenic Signaling: A Polypharmacology Approach.
Ranganna K; Selvam C; Shivachar A; Yousefipour Z
Int J Mol Sci; 2020 Nov; 21(21):. PubMed ID: 33147762
[TBL] [Abstract][Full Text] [Related]
15. Chemical Versatility in Catalysis and Inhibition of the Class IIb Histone Deacetylases.
Christianson DW
Acc Chem Res; 2024 Apr; 57(8):1135-1148. PubMed ID: 38530703
[TBL] [Abstract][Full Text] [Related]
16. Progress in discovery and development of natural inhibitors of histone deacetylases (HDACs) as anti-cancer agents.
Wahi A; Jain P; Sinhari A; Jadhav HR
Naunyn Schmiedebergs Arch Pharmacol; 2024 Feb; 397(2):675-702. PubMed ID: 37615708
[TBL] [Abstract][Full Text] [Related]
17. Class I and class II histone deacetylases are potential therapeutic targets for treating pancreatic cancer.
Wang G; He J; Zhao J; Yun W; Xie C; Taub JW; Azmi A; Mohammad RM; Dong Y; Kong W; Guo Y; Ge Y
PLoS One; 2012; 7(12):e52095. PubMed ID: 23251689
[TBL] [Abstract][Full Text] [Related]
18. Role of histone deacetylases and their inhibitors in cancer biology and treatment.
Beumer JH; Tawbi H
Curr Clin Pharmacol; 2010 Aug; 5(3):196-208. PubMed ID: 20406169
[TBL] [Abstract][Full Text] [Related]
19. Histone deacetylase (HDAC) inhibitors in cancer: a patent review (2017-present).
Zhao C; Dong H; Xu Q; Zhang Y
Expert Opin Ther Pat; 2020 Apr; 30(4):263-274. PubMed ID: 32008402
[No Abstract] [Full Text] [Related]
20. Development of histone deacetylase inhibitors for cancer treatment.
Marchion D; Münster P
Expert Rev Anticancer Ther; 2007 Apr; 7(4):583-98. PubMed ID: 17428177
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
